3.Consideration of therapy for colorectal cancer with synchronous unresectable liver metastasis.
De-xiang ZHU ; Li REN ; Jian-min XU
Chinese Journal of Gastrointestinal Surgery 2013;16(8):718-720
A variety of managements, including systemic and local chemotherapy, radiofrequency ablation and others, are used after multidisciplinary team discussion to improve the survival of patients with unresectable liver metastasis, and to enlarge the cohort of patients who can be managed with curative intent. Patients should be divided into different clinical groups according to characteristics of the patient and tumor, and then receive different treatments. For the patients who may be converted to be resectable after chemotherapy, we should choose efficient convertible chemotherapy with short courses to get the best response rate. For KRAS wild-type patients, cetuximab combined with FOLFOX/FOLFIRI, in which 5-fluorouracil is continuously infused, is recommended. In addition, resection of the primary tumor is recommended at the right time for asymptomatic patients with unresectable liver metastases. There is no consensus on the preferred treatment modality for systemic and local therapies.
Colorectal Neoplasms
;
drug therapy
;
pathology
;
surgery
;
therapy
;
Humans
;
Liver Neoplasms
;
drug therapy
;
secondary
;
surgery
4.Advances and challenges in neoadjuvant treatment for colorectal cancer liver metastasis.
Chinese Journal of Gastrointestinal Surgery 2021;24(10):919-924
Liver metastasis is the leading cause of death in patients with colorectal cancer. Since surgical resection alone has a high postoperative recurrence rate, neoadjuvant therapy as an important means is widely applied in order to reduce recurrence and improve survival. Progress has been achieved in many aspects of neoadjuvant therapy in colorectal cancer liver metastasis, such as eligible patients selection, optimal regimens and courses of chemotherapy. However, controversies still remain regarding the standards of resectability of lesions and the application of targeted drugs. Individualized treatments could be developed based on multidisciplinary teamwork to achieve the goal of 'resources integration and treatment stratification'.
Chemotherapy, Adjuvant
;
Colorectal Neoplasms/drug therapy*
;
Humans
;
Liver Neoplasms/drug therapy*
;
Neoadjuvant Therapy
;
Neoplasm Recurrence, Local
5.Current status and progress in gastric cancer with liver metastasis.
Chinese Medical Journal 2011;124(3):445-456
OBJECTIVEThis review discusses the current status and progress in studies on gastric cancer with liver metastasis (GCLM), involving the routes, subtypes, and prognosis of GCLM; the genes and molecules associated with metastasis; the feasibility and value of each imaging modality; and current treatment options.
DATA SOURCESThe data used in this review were mainly from Medline and PubMed published in English from 2005 to August 2010. The search terms were "gastric cancer" and "liver metastasis".
STUDY SELECTIONArticles regarding the characteristics, diagnostic modalities, and various therapeutic options of GCLM were selected.
RESULTSThe prognosis of GCLM is influenced by the clinicopathological characteristics of primary tumors, as well as the presence of liver metastases. Improved understanding of related genes and molecules will lead to the development of methods of early detection and targeted therapies. For the diagnosis of GCLM, each imaging modality has its relative benefits. There remains no consensus regarding therapeutic options.
CONCLUSIONSEarly detection and characterization of liver metastases is crucial for the prognosis of gastric cancer patients. Multidisciplinary team discussions are required to design optimal treatment strategies, which should be based on the clinicopathological characteristics of each patient.
Humans ; Liver Neoplasms ; diagnosis ; drug therapy ; secondary ; surgery ; Stomach Neoplasms ; complications ; diagnosis ; drug therapy ; surgery
6.Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma.
Journal of Liver Cancer 2016;16(1):1-6
Sorafenib is the standard treatment for advanced hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer staging system. However, because of its unsatisfactory efficacy, adverse effects, and high cost, the use of sorafenib is limited, and other treatment modalities are required. Recent studies reported that treatment modalities other than sorafenib, such as hepatic arterial infusion chemotherapy and transarterial radioembolization, showed comparable or better response rates and survival rates than sorafenib. In this review, treatment modalities that could be used as alternatives to sorafenib will be discussed.
Carcinoma, Hepatocellular*
;
Drug Therapy
;
Humans
;
Liver Neoplasms
;
Survival Rate
7.Hepatic resection after neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer: need for cautious planning
Young Il KIM ; In Ja PARK ; Jeong Eun KIM ; So Yeon KIM ; Jin Hong PARK ; Jae Hoon LEE ; Tae Yong HA ; Yong Sang HONG ; Sun Young KIM ; Tae Won KIM ; Seok Byung LIM ; Chang Sik YU ; Jin Cheon KIM
Annals of Surgical Treatment and Research 2019;97(5):245-253
PURPOSE: Current neoadjuvant chemotherapy (NAC) may enable therapies such as surgical resection and local ablation of metastases in patients with colorectal liver metastasis (CLM). We evaluated outcomes in CLM patients who underwent resection and/or local treatment after NAC and identified prognostic factors for oncologic outcomes. METHODS: Patients who received NAC followed by resection and/or local treatment of hepatic metastasis from 2013 to 2015 were included. Treatment and tumor-related variables were tabulated. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Cox regression analysis was used to identify factors associated with RFS and OS. RESULTS: Sixty-eight patients received NAC followed by resection and/or local treatment of hepatic metastases. Targeted therapy was administered in 50% of the patients. RFS was 35.8% at 1 year and 19.4% at 2 years postoperatively. OS was 95.6% at 1 year and 88.2% at 2 years postoperatively. In the multivariable analysis, R1 resection margin (hazard ratio [HR], 3.95; P = 0.008) of the liver metastases and ypN1/ypN2 (HR, 2.356 and 1.983, respectively; P = 0.041) were associated with poor RFS. Both factors were also significantly related to OS. CONCLUSION: Resection margin of the metastatic tumor and ypN status are the only relevant factors for RFS and OS in CLM patients treated with NAC. Despite early and high rates of recurrence, CLM patients treated with NAC who undergo resection and/or local treatment have acceptable OS. Multidisciplinary review of candidates for surgery and cautious planning are crucial for achieving optimal outcomes.
Colorectal Neoplasms
;
Drug Therapy
;
Humans
;
Liver
;
Methods
;
Neoplasm Metastasis
;
Recurrence
8.Non-surgical therapy for hepatocellular carcinoma.
Chinese Journal of Hepatology 2006;14(7):558-560
9.Infantile hemangioendothelioma treated with high dose methylprednisolone pulse therapy.
Eun Ae PARK ; Jung Wan SEO ; Sun Wha LEE ; Hae Young CHOI ; Seung Joo LEE
Journal of Korean Medical Science 2001;16(1):127-129
Infantile hemangioendothelioma is a severe disease with a high mortality. It is characterized by multiple hemangioma affecting the skin and visceral organs. We report that high doses of methylprednisolone pulse therapy improved symptoms and signs of infantile hemangioendothelioma in a male neonate, and completely resolved the hepatic and cutaneous hemangioendothelioma on follow up.
Case Report
;
Hemangioendothelioma/drug therapy*
;
Human
;
Infant, Newborn
;
Liver Neoplasms/drug therapy*
;
Male
;
Methylprednisolone/administration & dosage*
;
Skin Neoplasms/drug therapy*
10.Microcirculation of liver cancer, microenvironment of liver regeneration, and the strategy of Chinese medicine.
Chinese journal of integrative medicine 2016;22(3):163-167
Microcirculation of liver cancer is the micro-vascular system which comes from the tissue of liver cancer. It can offer the nutritional requirement for accelerating the cancer cell proliferation and metastasis. The intrinsic mechanism of angiogenesis is the key link in the formation of liver cancer microcirculation system. Liver regeneration microenvironment also plays an important role in the construction of liver cancer microcirculation, through the improvement of liver regeneration microenvironment affecting tumor microcirculation is the new strategy of prevention and treatment of liver cancer. In recent years, it is found that many kinds of Chinese medicine can inhibit angiogenesis, decrease the microvessel density, and delay or prevent the development of liver cancer.
Humans
;
Liver Neoplasms
;
drug therapy
;
pathology
;
therapy
;
Liver Regeneration
;
Medicine, Chinese Traditional
;
Microcirculation
;
Tumor Microenvironment